Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
PharmaCyte Biotech, Inc. PMCB
$3.06
-$0.03 (-0.97%)
На 17:33, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
48318218.00000000
-
week52high
3.10
-
week52low
1.95
-
Revenue
0
-
P/E TTM
-14
-
Beta
-0.03044900
-
EPS
-0.27000000
-
Last Dividend
0.00000000
-
Next Earnings Date
16 мар 2022 г. в 09:00
Описание компании
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Neutral | 08 ноя 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Allen Daniel | A | 125000 | 125000 | 28 дек 2022 г. |
| Farb Daniel Stuart | A | 125000 | 125000 | 28 дек 2022 г. |
Новостная лента
Is This A Good Time To Invest In PharmaCyte?
Seeking Alpha
07 янв 2022 г. в 02:59
Is This A Good Time To Invest In PharmaCyte?
3 Penny Stocks Waiting on FDA Approval for Rocket Fuel
InvestorPlace
18 окт 2021 г. в 06:00
Several penny stocks out there have done very well recently but these three biotechs are waiting for positive FDA news to soar higher. The post 3 Penny Stocks Waiting on FDA Approval for Rocket Fuel appeared first on InvestorPlace.